MY208313A - Compositions and methods for treating brain injury - Google Patents

Compositions and methods for treating brain injury

Info

Publication number
MY208313A
MY208313A MYPI2020001313A MYPI2020001313A MY208313A MY 208313 A MY208313 A MY 208313A MY PI2020001313 A MYPI2020001313 A MY PI2020001313A MY PI2020001313 A MYPI2020001313 A MY PI2020001313A MY 208313 A MY208313 A MY 208313A
Authority
MY
Malaysia
Prior art keywords
compositions
methods
brain injury
treating brain
treating
Prior art date
Application number
MYPI2020001313A
Other languages
English (en)
Inventor
Michael J Brownstein
Original Assignee
Azevan Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Azevan Pharmaceuticals Inc filed Critical Azevan Pharmaceuticals Inc
Publication of MY208313A publication Critical patent/MY208313A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MYPI2020001313A 2017-09-15 2018-09-17 Compositions and methods for treating brain injury MY208313A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762559113P 2017-09-15 2017-09-15
US201762584343P 2017-11-10 2017-11-10
US201862658758P 2018-04-17 2018-04-17
PCT/US2018/051331 WO2019055913A1 (en) 2017-09-15 2018-09-17 COMPOSITIONS AND METHODS FOR TREATMENT OF BRAIN INJURY

Publications (1)

Publication Number Publication Date
MY208313A true MY208313A (en) 2025-04-30

Family

ID=65723435

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2020001313A MY208313A (en) 2017-09-15 2018-09-17 Compositions and methods for treating brain injury

Country Status (14)

Country Link
US (2) US11628160B2 (enExample)
EP (1) EP3681871A4 (enExample)
JP (2) JP2020534274A (enExample)
KR (1) KR102790657B1 (enExample)
CN (1) CN111295373B (enExample)
AU (1) AU2018333051B2 (enExample)
BR (1) BR112020005107A2 (enExample)
CA (1) CA3075759A1 (enExample)
IL (1) IL273228B2 (enExample)
MX (1) MX2020002762A (enExample)
MY (1) MY208313A (enExample)
TW (1) TW201919625A (enExample)
WO (1) WO2019055913A1 (enExample)
ZA (1) ZA202001880B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2804001C (en) 2010-07-01 2021-02-09 Azevan Pharmaceuticals, Inc. Methods for treating post traumatic stress disorder
DK3122743T3 (da) 2014-03-28 2023-02-20 Azevan Pharmaceuticals Inc Sammensætninger og fremgangsmåder til behandling af neurodegenerative sygdomme
CA3018375A1 (en) * 2016-03-30 2017-10-05 Carin Sjolund Negative allosteric modulators of mglur5 for use in the treatment of mature brain damages
JP2020534274A (ja) * 2017-09-15 2020-11-26 アゼヴァン ファーマシューティカルズ，インコーポレイテッド 脳損傷を治療するための組成物及び方法
US11583538B2 (en) 2019-04-08 2023-02-21 Venenum Biodesign, LLC Substituted pyrrolo[1,2-a]pyrazines and pyrrolo[1,2-a][1,4]diazepines as TREX1 inhibitors
WO2022075974A1 (en) * 2020-10-06 2022-04-14 Venenum Biodesign, LLC Cyclic trex1 inhibitors
CN115350186A (zh) * 2022-08-31 2022-11-18 中国人民解放军军事科学院军事医学研究院 Sxr246在制备治疗创伤性脑损伤及预后不良药物中的应用

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1422263A (en) 1973-01-30 1976-01-21 Ferrosan As 4-phenyl-piperidine compounds
US4314081A (en) 1974-01-10 1982-02-02 Eli Lilly And Company Arloxyphenylpropylamines
NL7503310A (nl) 1975-03-20 1976-09-22 Philips Nv Verbindingen met antidepressieve werking.
US4576753A (en) 1975-10-06 1986-03-18 Fujisawa Pharmaceutical Co., Ltd. Azetidinone compounds and processes for preparation thereof
GB1526331A (en) 1976-01-14 1978-09-27 Kefalas As Phthalanes
US4341698A (en) 1979-06-21 1982-07-27 Richardson-Merrell Inc. Enkaphalin derivatives
US4536518A (en) 1979-11-01 1985-08-20 Pfizer Inc. Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
JPS6033439B2 (ja) 1980-03-07 1985-08-02 財団法人相模中央化学研究所 ジペプチドの製造方法
JPS56125361A (en) 1980-03-07 1981-10-01 Sagami Chem Res Center Azetidinone compound
FR2508035A1 (fr) 1981-06-23 1982-12-24 Fabre Sa Pierre Derives d'aryl-1-aminomethyl-2 cyclopropanes carboxamides (z), leur preparation et leur application en tant que medicaments utiles dans le traitement des troubles du systeme nerveux central
US4761501A (en) 1983-10-26 1988-08-02 American Home Products Corporation Substituted phenylacetamides
US4751299A (en) 1983-11-18 1988-06-14 Takeda Chemical Industries, Ltd. Optically active β-lactams and method of their production
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4734498A (en) 1986-07-10 1988-03-29 Eli Lilly And Company 3β-succinimidoazetidinones as chiral intermediates
US4772694A (en) 1986-07-24 1988-09-20 Eli Lilly And Company Chiral 3-(1,2,5-trisubstituted imidazolidinone) azetidinone antibiotic intermediates
US4956388A (en) 1986-12-22 1990-09-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
WO1992005784A1 (en) 1990-10-02 1992-04-16 Warner-Lambert Company 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine derivatives and analogues as angiotensin ii receptor antagonists
GB9204001D0 (en) 1992-02-25 1992-04-08 Jacobs Suchard Ag Process for producing reduced fat nuts
US5246943A (en) 1992-05-19 1993-09-21 Warner-Lambert Company Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties
WO1994001402A1 (en) 1992-07-13 1994-01-20 Merck Sharp & Dohme Limited Heterocyclic amide derivatives as tachykinin derivatives
JP3507494B2 (ja) 1992-08-13 2004-03-15 ワーナー−ランバート・コンパニー タキキニン拮抗薬
FR2696178B1 (fr) 1992-09-30 1994-12-30 Sanofi Elf Amides basiques quaternaires, procédé pour leur préparation et compositions pharmaceutiques en contenant.
NZ267209A (en) 1993-05-06 1997-09-22 Merrell Dow Pharma Substituted pyrrolidin-3-yl-alkyl-piperidine derivatives, preparation and pharmaceutical compositions thereof
US5512563A (en) 1993-07-29 1996-04-30 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
US5759865A (en) 1995-05-03 1998-06-02 Eli Lilly And Company Combinatorial process for synthesizing azetidinone analogs
GB9511694D0 (en) 1995-06-09 1995-08-02 Fujisawa Pharmaceutical Co Benzamide derivatives
CA2246753C (en) 1996-02-23 2005-05-10 Eli Lilly And Company Non-peptidyl vasopressin v1a antagonists
AU5597098A (en) 1996-12-13 1998-07-03 Eli Lilly And Company Inhibitors of the enzymatic activity of psa
AU732214C (en) 1997-03-31 2001-10-25 Wakamoto Pharmaceutical Co., Ltd. Biphenyl derivatives and drug composition
HUP0002480A3 (en) 1997-07-30 2002-09-30 Wyeth Corp Pyrrolo[2,1-c][1,4]benzodiazepine derivatives, their use, process for their preparation and pharmaceutical compositions containing them
US6403632B1 (en) 2000-03-01 2002-06-11 Bristol Myers Squibb Pharma Co Lactam metalloprotease inhibitors
KR100517644B1 (ko) 1997-10-27 2005-09-28 닥터 레디스 레보러터리즈 리미티드 신규의 삼원 화합물 및 그 약학적 용도, 그 제조방법 및이들을 포함하는 약제학적 조성물
WO2001012184A1 (en) 1999-08-16 2001-02-22 Revaax Pharmaceuticals, Llc Neurotherapeutic composition and method
GB0019006D0 (en) 2000-08-04 2000-09-20 Astrazeneca Ab Novel compounds
CA2462903C (en) 2001-10-12 2011-09-20 Serenix Pharmaceuticals, Llc Beta-lactamyl vasopressin v1a antagonists
US7179907B2 (en) 2001-12-18 2007-02-20 Bruce Eaton Antibiotic compounds
US7135479B2 (en) 2002-09-12 2006-11-14 Wyeth Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans
GB0224919D0 (en) 2002-10-25 2002-12-04 Pfizer Ltd Triazole compounds useful in therapy
WO2005007658A2 (en) 2003-07-14 2005-01-27 Arena Pharmaceuticals, Inc. Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
US20060281728A1 (en) 2003-10-03 2006-12-14 Guillon Christophe D 3-Substituted beta-lactamyl vasopressin v1a antagonists
US7745630B2 (en) 2003-12-22 2010-06-29 Justin Stephen Bryans Triazolyl piperidine arginine vasopressin receptor modulators
EP1632494A1 (en) 2004-08-24 2006-03-08 Ferring B.V. Vasopressin v1a antagonists
EP1669776A1 (de) 2004-12-11 2006-06-14 Leica Geosystems AG Handhaltbares Vermessungsgerät und Vermessungsverfahren für ein solches Vermessungsgerät
FR2881744B1 (fr) 2005-02-09 2007-04-27 Sanofi Aventis Sa Derives de n-[(4,5-diphenyl-2-thienyl)methyl]amine, leur preparation et leur application en therapeutique
EP1868434A4 (en) 2005-03-22 2011-10-26 Azevan Pharmaceuticals Inc BETA-LACTAMYL ALKANIC ACIDS FOR THE TREATMENT OF PREMIERSTRUELLEN FAULTS
JP2008540633A (ja) 2005-05-18 2008-11-20 ファイザー・リミテッド バソプレッシン拮抗薬としての１，２，４−トリアゾール誘導体
ES2726942T3 (es) 2005-07-19 2019-10-10 Azevan Pharmaceuticals Inc Antagonista de vasopresina de tipo beta-lactamil fenilalanina, cisteína y serina
WO2007109615A2 (en) 2006-03-21 2007-09-27 Azevan Pharmaceuticals, Inc. β -LACTAMYL VASOPRESSIN V2 ANTAGONISTS
WO2008034032A2 (en) 2006-09-14 2008-03-20 Azevan Pharmaceuticals, Inc. Beta-lactam cannabinoid receptor modulators
JP2010504352A (ja) 2006-09-22 2010-02-12 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ バソプレッシン拮抗薬としてのスピロベンズアゼピン類
US7825110B2 (en) * 2006-09-22 2010-11-02 Janssen Pharmaceutica Nv Substituted spiroheterocycles
JP5450108B2 (ja) 2007-03-23 2014-03-26 アレイ バイオファーマ、インコーポレイテッド グルコキナーゼ活性化剤としての２−アミノピリジン類似体
FR2927625B1 (fr) 2008-02-19 2010-03-12 Sanofi Aventis Nouveaux derives de 3-aminoalkyl-1,3-dihydro-2h-indol-2-one, leur preparation et leur application en therapeutique
FR2930249B1 (fr) 2008-04-21 2010-05-14 Sanofi Aventis Nouveaux derives de 3-aminoalkyl-1,3-dihydro-2h-indol-2-one, leur preparation et leur application en therapeutique.
CA2804001C (en) * 2010-07-01 2021-02-09 Azevan Pharmaceuticals, Inc. Methods for treating post traumatic stress disorder
CN102156420B (zh) 2010-12-23 2012-11-07 天津职业技术师范大学 加快从计算机下载数据到单片机目标存储器的装置
CA2901577A1 (en) * 2013-02-18 2014-08-21 The Scripps Research Institute Modulators of vasopressin receptors with therapeutic potential
DK3122743T3 (da) * 2014-03-28 2023-02-20 Azevan Pharmaceuticals Inc Sammensætninger og fremgangsmåder til behandling af neurodegenerative sygdomme
JP2020534274A (ja) * 2017-09-15 2020-11-26 アゼヴァン ファーマシューティカルズ，インコーポレイテッド 脳損傷を治療するための組成物及び方法

Also Published As

Publication number Publication date
TW201919625A (zh) 2019-06-01
JP2020534274A (ja) 2020-11-26
US20240115553A1 (en) 2024-04-11
AU2018333051B2 (en) 2024-03-21
IL273228A (en) 2020-04-30
ZA202001880B (en) 2022-06-29
WO2019055913A1 (en) 2019-03-21
EP3681871A1 (en) 2020-07-22
EP3681871A4 (en) 2021-05-26
BR112020005107A2 (pt) 2020-11-03
KR102790657B1 (ko) 2025-04-02
CN111295373B (zh) 2024-12-10
JP7699634B2 (ja) 2025-06-27
IL273228B1 (en) 2024-12-01
IL273228B2 (en) 2025-04-01
MX2020002762A (es) 2020-09-17
AU2018333051A1 (en) 2020-03-26
RU2020110038A (ru) 2021-10-15
US11628160B2 (en) 2023-04-18
US20200276167A1 (en) 2020-09-03
KR20200071075A (ko) 2020-06-18
CA3075759A1 (en) 2019-03-21
JP2023179559A (ja) 2023-12-19
RU2020110038A3 (enExample) 2021-10-15
CN111295373A (zh) 2020-06-16

Similar Documents

Publication Publication Date Title
MY208313A (en) Compositions and methods for treating brain injury
MX2018009325A (es) Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn).
NZ742787A (en) Compositions comprising bacterial strains
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
PH12020500371A1 (en) Spirocycle compounds and methods of making and using same
GB2541571A (en) Pharmaceutical compositions
EP4520828A3 (en) Compositions and methods for the treatment of aberrant angiogenesis
PH12020500372A1 (en) Spirocycle compounds and methods of making and using same
IL272055A (en) 8,1-naphthyridinone compounds and their uses
ZA201904387B (en) Compositions and methods for treating, ameliorating and preventing h. pylori
MY196448A (en) Anti-Htra1 Antibodies and Methods of use Thereof
MA48939B1 (fr) Compositions comprenant des souches bactériennes
WO2015143447A3 (en) Methods for treating neurological disorders
IL271728A (en) Materials, uses and treatment methods
WO2017120527A3 (en) Therapeutic compositions and methods for treating hepatitis b
IL284765A (en) 8,1-naphthyridinone compounds and their uses
MX382092B (es) Compuestos heterocíclicos para el tratamiento de enfermedades.
IL286646A (en) Preparations, devices and methods for the treatment of Fabry disease
MX2020000636A (es) Proteinas sinteticas y usos terapeuticos de las mismas.
PH12021550121A1 (en) Methods of treating hfpef employing dapagliflozin and compositions comprising the same
WO2018211324A8 (en) Prodrugs for the treatment of disease
WO2018211323A8 (en) Heterocyclic compounds for the treatment of disease
WO2017161344A8 (en) Compositions and methods for treating parasitic diseases
PH12019502145A1 (en) Agent for preventing myopia, treating myopia, and/or preventing myopia progression comprising tiotropium as active ingredient
MX2018010919A (es) Procedimiento para el tratamiento termico de un producto plano de acero, producto plano de acero tratado termicamente asi como su uso.